Omeros

Omeros ( OMER) is hoping to win in the marketplace by mixing a cocktail of existing drugs to preemptively curb inflammation during surgery.

But finding commercial success with these PharmacoSurgery products won't be easy. "Rather than developing novel therapies of its own, Omeros simply repackages over-the-counter and prescription generic medications for use in its drug delivery system," Morningstar wrote in a note. "And without a novel product on its hands or a critical unmet need to address, surgeons could be hesitant to replace their current treatment practices with Omeros' pricier offerings."

Omeros began trading on Oct. 8, pricing its 6.82 million shares at $10. But investors, unsure about the company's long-term potential, have since sent shares in Omeros plunging by 30% to close at $7.01 on Dec. 8.

In the third quarter, Omeros reported a loss of $3.9 million or $1.34 a share, compared to a loss of $7.4 million or $2.54, in the year-ago quarter.

If you liked this article you might like

Netflix Investors: Don't Be Wooed by an Earnings Beat

eBay's Earnings a Mixed Bag

Hulu to Develop Original Series 'Battleground'

Angry Netflix Investors Fight Back

Best Buy Shuffles Management Ranks